These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28837373)
1. Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials. Reeder-Hayes KE; Roberts MC; Henderson GE; Dees EC J Oncol Pract; 2017 Oct; 13(10):e863-e873. PubMed ID: 28837373 [TBL] [Abstract][Full Text] [Related]
2. Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation. Halpern J; Paolo D; Huang A J Med Ethics; 2019 Jun; 45(6):384-387. PubMed ID: 31189726 [TBL] [Abstract][Full Text] [Related]
3. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866 [TBL] [Abstract][Full Text] [Related]
4. Phase 1 oncology trials and informed consent. Miller FG; Joffe S J Med Ethics; 2013 Dec; 39(12):761-4. PubMed ID: 23161617 [TBL] [Abstract][Full Text] [Related]
5. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. Partridge AH; Sepucha K; O'Neill A; Miller KD; Motley C; Swaby RF; Schneider BP; Dang CT; Northfelt DW; Sledge GW JAMA Oncol; 2015 Jun; 1(3):369-74. PubMed ID: 26114161 [TBL] [Abstract][Full Text] [Related]
6. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Miller FG; Joffe S Clin Trials; 2008; 5(6):617-23. PubMed ID: 19029210 [TBL] [Abstract][Full Text] [Related]
7. Study of cohort-specific consent and patient control in phase I cancer trials. Daugherty CK; Ratain MJ; Minami H; Banik DM; Vogelzang NJ; Stadler WM; Siegler M J Clin Oncol; 1998 Jul; 16(7):2305-12. PubMed ID: 9667244 [TBL] [Abstract][Full Text] [Related]
8. Healthy participants in phase I clinical trials: the quality of their decision to take part. Rabin C; Tabak N J Clin Nurs; 2006 Aug; 15(8):971-9. PubMed ID: 16879541 [TBL] [Abstract][Full Text] [Related]
9. Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Stryker JE; Wray RJ; Emmons KM; Winer E; Demetri G Patient Educ Couns; 2006 Oct; 63(1-2):104-9. PubMed ID: 16242898 [TBL] [Abstract][Full Text] [Related]
10. Nothing to lose: a grounded theory study of patients' and healthcare professionals' perspectives of being involved in the consent process for oncology trials with non-curative intent. Murphy M; McCaughan E; Carson MA; Donovan M; Wilson RH; Fitzsimons D BMC Palliat Care; 2020 Oct; 19(1):166. PubMed ID: 33126874 [TBL] [Abstract][Full Text] [Related]
11. Benefit Mixed with Caution for Buparlisib. Cancer Discov; 2017 Feb; 7(2):121. PubMed ID: 27986714 [TBL] [Abstract][Full Text] [Related]
12. Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Schutta KM; Burnett CB Oncol Nurs Forum; 2000 Oct; 27(9):1435-8. PubMed ID: 11058975 [TBL] [Abstract][Full Text] [Related]
13. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced gastric cancer. Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174 [TBL] [Abstract][Full Text] [Related]
15. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related]
16. Potential subjects' responses to an ethics questionnaire in a phase I study of deep brain stimulation in early Parkinson's disease. Finder SG; Bliton MJ; Gill CE; Davis TL; Konrad PE; Charles PD J Clin Ethics; 2012; 23(3):207-16. PubMed ID: 23256400 [TBL] [Abstract][Full Text] [Related]
17. Picking and Choosing Among Phase I Trials : A Qualitative Examination of How Healthy Volunteers Understand Study Risks. Fisher JA; Monahan T; Walker RL J Bioeth Inq; 2019 Dec; 16(4):535-549. PubMed ID: 31713712 [TBL] [Abstract][Full Text] [Related]
18. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
20. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]